Peroxisome proliferator-activated receptor γ2 Pro12Ala (rs1801282) polymorphism and breast cancer susceptibility: a meta-analysis.

Several studies have investigated the correlation between the peroxisome proliferator-activated receptor γ2 (PPAR‑γ2) Pro12Ala (rs1801282) polymorphism and the risk of breast cancer, with inconsistent results. For this reason, a meta-analysis was conducted to identify the potential correlation after pooling data from eligible case-control studies. Search strategies were conducted in PubMed, EMBASE and the COCHRANE Library in English and from VIP, CNKI and Sinomed in Chinese (all the papers were published before November 11, 2012) using appropriate terms. A total of 2,279 cases and 2,360 controls from four related case-control studies were included in this meta-analysis. According to the three eligible populations, the odds ratios (ORs) and 95% confidence intervals (CIs) on the risk of breast cancer for the CG versus CC and GG versus CC genotypes and the G versus C allele were 0.84 and 0.72-0.98, 0.92 and 0.32-2.61, and 0.98 and 0.84-1.13, respectively. The OR and 95% CI for CG+GG versus CC from the four study populations were 0.85 and 0.73-0.98, respectively. This meta-analysis supported the fact that the G allele of PPAR‑γ2 Pro12Ala (rs1801282) modestly affects the risk of breast cancer. Nevertheless, further studies are required to enrich the evidence of this correlation.

[1]  Hongwei Wang,et al.  The Alcohol Dehydrogenase 1C(rs698) Genotype and Breast Cancer , 2015, Asia-Pacific journal of public health.

[2]  N. Shen,et al.  A Common Polymorphism near the ESR1 Gene Is Associated with Risk of Breast Cancer: Evidence from a Case-Control Study and a Meta-Analysis , 2012, PloS one.

[3]  Jianqiu Chen,et al.  Association of MHTFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: An update meta-analysis based on 51 research studies , 2012, Diagnostic Pathology.

[4]  Li-wen Li,et al.  Menopausal status modifies breast cancer risk associated with ESR1 PvuII and XbaI polymorphisms in Asian women: a HuGE review and meta-analysis. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[5]  J. Chan,et al.  Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population. , 2012, Diabetes research and clinical practice.

[6]  A. Shin,et al.  Polymorphisms in adiposity-related genes are associated with age at menarche and menopause in breast cancer patients and healthy women. , 2012, Human reproduction.

[7]  S. Awasthi,et al.  Association of PPAR‐γ gene polymorphisms with obesity and obesity‐associated phenotypes in north indian population , 2012, American journal of human biology : the official journal of the Human Biology Council.

[8]  T. Molnár,et al.  Association of peroxisome proliferator‐activated receptor gamma polymorphisms with inflammatory bowel disease in a Hungarian cohort , 2012, Inflammatory bowel diseases.

[9]  A. Alsaleh,et al.  PPARγ2 Gene Pro12Ala and PPARα Gene Leu162Val Single Nucleotide Polymorphisms Interact with Dietary Intake of Fat in Determination of Plasma Lipid Concentrations , 2012, Lifestyle Genomics.

[10]  K. Kristiansen,et al.  PPARgamma-PGC-1alpha activity is determinant of alcohol related breast cancer. , 2012, Cancer letters.

[11]  D. Stram,et al.  Genetic Variation in Peroxisome Proliferator–Activated Receptor Gamma, Soy, and Mammographic Density in Singapore Chinese Women , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[12]  Chien‐An Sun,et al.  Joint effect of peroxisome proliferator-activated receptor γ genetic polymorphisms and estrogen-related risk factors on breast cancer risk: results from a case–control study in Taiwan , 2011, Breast Cancer Research and Treatment.

[13]  K. Czene,et al.  Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer , 2011, Breast Cancer Research.

[14]  A. Southwick,et al.  Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease , 2009, PPAR research.

[15]  F. Ondrey,et al.  Peroxisome Proliferator-Activated Receptor γ Pathway Targeting in Carcinogenesis: Implications for Chemoprevention , 2009, Clinical Cancer Research.

[16]  S. Paik,et al.  Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders , 2008, PPAR research.

[17]  K. Hemminki,et al.  Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. , 2006, Carcinogenesis.

[18]  U. Vogel,et al.  Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. , 2006, Carcinogenesis.

[19]  G. Colditz,et al.  No evidence of a role for PPARgamma Pro12Ala polymorphism in endometrial cancer susceptibility. , 2004, Pharmacogenetics.

[20]  A. von Deimling,et al.  Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[21]  J. Manson,et al.  Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor gamma gene with breast cancer and body mass. , 2002, Pharmacogenetics.

[22]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[23]  魏光伟.  Evaluating the prognostic significance of FBXW7 expression level in human breast cancer by a meta-analysis of transcriptional profiles , 2012 .

[24]  K. Ickstadt,et al.  Breast cancer: a candidate gene approach across the estrogen metabolic pathway , 2007, Breast Cancer Research and Treatment.

[25]  M. Thun,et al.  Nested case-control study of energy regulation candidate gene single nucleotide polymorphisms and breast cancer. , 2007, Anticancer research.

[26]  K. Helzlsouer,et al.  Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. , 2007, Cancer detection and prevention.